SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-24-000353
Filing Date
2024-01-02
Accepted
2024-01-02 16:30:25
Documents
14
Period of Report
2023-12-27
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2334004d1_8k.htm   iXBRL 8-K 35620
2 EXHIBIT 99.1 tm2334004d1_ex99-1.htm EX-99.1 10739
  Complete submission text file 0001104659-24-000353.txt   272613

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA aktx-20231227.xsd EX-101.SCH 3541
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE aktx-20231227_def.xml EX-101.DEF 26894
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE aktx-20231227_lab.xml EX-101.LAB 36553
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE aktx-20231227_pre.xml EX-101.PRE 25518
8 EXTRACTED XBRL INSTANCE DOCUMENT tm2334004d1_8k_htm.xml XML 4958
Mailing Address 22 BOSTON WHARF ROAD FL 7 BOSTON MA 02210
Business Address 22 BOSTON WHARF ROAD FL 7 BOSTON MA 02210 (646) 350-0702
Akari Therapeutics Plc (Filer) CIK: 0001541157 (see all company filings)

IRS No.: 981034922 | State of Incorp.: X0
Type: 8-K | Act: 34 | File No.: 001-36288 | Film No.: 24502883
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)